[ad_1] The media coverage of Dicerna Pharmaceuticals (NASDAQ: DRNA) has been rather positive recently, reports Accern Sentiment Analysis. Accern ranks corporate coverage on a scale from negative to positive, with scores closest …
Read More »Dicerna Pharmaceuticals (NASDAQ: DRNA): a rather favorable report
